The pharmaceutical industry has called for abolishing “off-year” drug price revisions in the run-up to the formulation of the 2024 Basic Policy on Economic and Fiscal Management and Reform (honebuto) later in June. It appears that its lobbying efforts have…
HOME > LATEST
LATEST
-
BUSINESS Daiichi Sankyo Files MMR Vaccine in Japan
March 26, 2024
-
BUSINESS Hospitalized Cases Tied to Kobayashi Pharma’s Supplements Now Up to 26
March 26, 2024
-
BUSINESS Lilly, Nippon Shinyaku Pair Up on Blood Cancer Med in Japan
March 26, 2024
-
REGULATORY Japan’s 1st Eylea Biosimilar Approval on Horizon? JAN Now Decided
March 25, 2024
-
BUSINESS Daiichi Sankyo Eyes 7 Additional Indications for Enhertu by 2026
March 25, 2024
-
BUSINESS Ono Hooks Up with Oxford on Drug Discovery Research
March 25, 2024
-
BUSINESS EMA Delays Decision on Leqembi Due to Procedural Issues
March 25, 2024
-
BUSINESS Iclusig Gets Additional FDA Nod for Iclusig in Ph+ ALL: Takeda
March 25, 2024
-
BUSINESS Novartis, Sandoz Recall Entacapone Products over Carcinogenic Risk
March 25, 2024
-
BUSINESS Kobayashi Pharma Recalls Supplements on Reports of Kidney Disorders
March 25, 2024
-
REGULATORY Chuikyo Agrees to Exempt PD-1/PD-L1, JAK Classes from Spillover Re-Pricing
March 25, 2024
-
REGULATORY Xocova’s Price to Remain Intact after Full Approval, No Change in Clinical Positioning
March 25, 2024
-
BUSINESS Combined Sales of 26 Japan Drug Makers Up 13.6% in FY2022 on Global Growth, COVID Demand
June 22, 2023
ページ
The pharmaceutical industry is ever-changing. Recruiters must evolve accordingly and prepare well in advance for future talent needs.This means predicting the changes and trends that will impact the market, industry, and your organization, and how this will affect talent requirements.…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…